AIDS · 2007 · 12 citations · 10 references
Surrogate MarkersDiagnosisPathologyLiver BiopsyCirrhosisAutoimmune Liver DiseaseThrombosisViral HepatitisHematologyHepatology FibrosisMolecular DiagnosticsHealth SciencesHiv/hepatitis C-co-infected PatientsLiver PhysiologyHistopathologyChronic Viral InfectionHivEpidemiologyHepatologyAntiviral TherapyHepatitisLiver DiseaseMedicineAspartate Aminotransferase/plateletAdvanced Disease
Liver biopsy is currently the gold standard for determining the stage of liver fibrosis. There are risks associated with liver biopsy; therefore, surrogate markers to predict the severity of disease would be useful. We studied 50 patients with HIV/hepatitis C co-infection who had liver biopsies and determined that no patient with an aspartate aminotransferase/platelet ratio index (APRI) of 0.6 or less had stage F3 or F4 disease. The APRI is useful for excluding advanced disease in this patient population.
10